Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents

Table 1 Clinical outcomes at 12 mo and 24 mo¹

Clinical outcomes	At 12 mo		At 24 mo		HR (95%CI)2	P
	Clopidogrel + aspirin	Aspirin alone	Clopidogrel + aspirin	Aspirin alone	Clopidogrel + aspirin	Aspirin alone
Primary end point: MI or death from cardiac causes	0.7	0.5	1.8	1.2	1.65 (0.80-3.36)	0.17
Secondary end points
Death from any cause	0.5	0.5	1.6	1.4	1.52 (0.75-3.50)	0.24
MI	0.4	0.3	0.8	0.7	1.41 (0.54-3.71)	0.49
Stroke	0.3	0.3	1.0	0.3	2.22 (0.68-7.20)	0.19
Stent thrombosis, definite	0.2	0.1	0.4	0.4	1.23 (0.33-4.58)	0.76
Repeat revascularization	1.7	1.1	3.1	2.4	1.37 (0.83-2.27)	0.22
MI or death from any cause	0.8	0.8	2.3	1.7	1.57 (0.85-2.88)	0.15
MI, stroke, or death from any cause	1.1	1.1	3.2	1.8	1.73 (0.99-3.00)	0.05
MI, stroke, or death from cardiac causes	1.0	0.8	2.7	1.3	1.84 (0.99-3.45)	0.06
Major bleeding, according to TIMI criteria	0.2	0.1	0.2	0.1	2.96 (0.31-28.46)	0.35

¹For the total number of events for each type of end point, only the first event is counted. Cumulative rates of events are based on Kaplan-Meier estimates. All deaths were considered to be from cardiac causes unless an unequivocal noncardiac cause could be established;

²Hazard ratios are for the dual-therapy group as compared with the aspirin-alone group. MI: Myocardial infarction; TIMI: Thrombolysis in myocardial infarction. (Modified from Ref. [7]).